Hong Kong-listed ophthalmic services group C-MER Medical Holdings Limited reported the repurchase of 106,000 ordinary shares on 17 September 2026, according to its Next Day Disclosure Return filed with the Stock Exchange of Hong Kong.

The on-market buyback, executed at prices between HK$0.83 and HK$0.85 per share, was settled at a volume-weighted average price of HK$0.8381, bringing the total cash outlay to HK$0.09 million. All repurchased shares have been retained as treasury shares.

Following the transaction, C-MER Medical’s issued share capital (excluding treasury shares) decreased from 1.20809 billion to 1.20799 billion shares—a 0.0088% reduction. Concurrently, the company’s treasury share balance rose from 24.25 million to 24.35 million shares. The total number of issued shares remains unchanged at 1.23234 billion.

The repurchase formed part of the mandate approved by shareholders on 20 May 2026, which authorizes the company to buy back up to 123.23 million shares. To date, only 106,000 shares, equivalent to 0.0086% of the company’s issued share count at the time of mandate approval, have been repurchased under this authority.

Under Hong Kong listing rules, C-MER Medical is subject to a moratorium on issuing new shares or disposing of treasury shares until 17 October 2026.